Close Menu

People in the News

Jul 02, 2019

Grace Colón

CareDx has appointed Grace Colón to its board of directors.  Colón currently served as president, CEO, and director of InCarda Therapeutics. She is also executive chairman of ProterixBIo and is on the board of Cocoon Biotech. Colón previously served on the boards of Paradigm Diagnostics and PerceptiMed. Colón has also served as a partner at New Science Ventures and held various leadership roles at Intrexon, Gilead Sciences, and Affymetrix. She will succeed Amy Abernethy on CareDx's board. 

Jul 01, 2019

David Rubin, Timothy Harris

David Rubin and Timothy Harris informed OpGen that they would be leaving the company's board, effective June 30. OpGen disclosed the resignations in a document filed with US Securities and Exchange Commission on July 1. Both had been on OpGen's board since 2015. The company said there had been no disagreement with Rubin or Harris leading to their resignations. 

Jul 01, 2019

Aamir Ali, Gary Falk, John Inadomi,

Cernostics has formed its medical advisory board, including Aamir Ali, Gary Falk, John Inadomi, Richard Lash, Nicholas Shaheen, and Sachin Wani. According to the firm, the members of board have been invovled in developing and publishing several BE and CE guidelines, participating in major BE clincal and research initiatives, and have served on the editorial boards of major gastroenterology journals. 

Ali is an associate director of research at Capital Digestic Care and consulting chief medical officer at Meridian Bioscience. Falk is a professor of medicine at the University of Pennsylvania Perelman School of Medicine and  the clinical co-director of the Esophagology and Swallowing Center. John Inadomi is the division head of gastroenterology at the University of Washington School of Medicine. Lash is president of R Lash MD Consulting and an associate clinical professor of Pathology at UT-Southwestern Medical Center. Shaheen is a professor of medicine at the University of North Carolina School of Medicine, as well as the chief of the gasteroenterology and hepatology center at UNC HealthCare. Wani is an associate professor of medicine, gastroenterology and medical director of the esophageal and gastric center at the University of Colorado School of Medicine. 

Jul 01, 2019

Keith Kennedy

Veracyte has appointed Keith Kennedy as chief operating officer. Prior to joining Veracyte, Kennedy served as executive leadership positions at MCG Capital, Arlington Capital Partners, and GE Capital over the past 20 years.

Jun 28, 2019

Eugene Durenard, Ted Murphy

Co-Diagnostics have appointed Eugene Durenard and Ted Murphy to its board of directors, and will serve on the board's compensation and corporate governance/nomination committees and audit committees as independent directors. The two new members will be replacing Frank Kiesnar, who resigned as director of the firm, and Edward Borkowski, who retired as a director of the firm.

Durenard has been founder and CEO of Hyperbolic Holdings since 2018, co-founder and chief innovation officer of Healthcare Impact Holdings since May 2018, co-founder and trustee of Healthcare Impact Foundation since 2017, co-founder of Global Better Health since December 2018, as well as advisor and managing director of the Stetson Family Office since September 2016.

Murphy serves on the board of directors of three Canadian publicly reporting companies, as well as a senior partner in a private investment firm since 1999.

Jun 27, 2019

Thomas West

Hologic announced that Thomas West, its diagnostics division president, resigned effective July 1. In a filing with the US Securities and Exchange Commission, the firm said he is leaving Hologic to assume the role of CEO at another publicly traded company.

Jun 26, 2019

Christopher Bird

Christopher Bird has been appointed CMO of Danish IVD firm BioPorto, effective Aug. 1. He was previously at Roche Diagnostics where he headed the North American Medical and Scientific Affairs organization. At BioPorto, he will be responsible for building, executing, and overseeing the company's diagnostic product development strategy. 

Jun 25, 2019

Rupert Vessey

Bio-Techne appointed Rupert Vessey as an independent director to its board of directors, bringing the total number of board members to nine.

He is the president of global research and early development at Celgene. Before joining Celgene, Vessey held various R&D senior management positions at Merck. Previously, he worked in drug discovery, experimental medicine, and early clinical development at GlaxoSmithKline.

Jun 25, 2019

Eric Rasmussen, Bryan Baldasare

Meridian Bioscience has announced that Eric Rasmussen has resigned his position as executive vice president and CFO effective June 28, 2019 in order to pursue other opportunities. Meridian has appointed Bryan Baldasare, currently its senior vice president, corporate controller, treasurer, and chief accounting officer, to serve as interim CFO.

Jun 24, 2019

Patrick Balthrop

Oxford Immunotec Global has appointed Patrick Balthrop as chairman of its board of directors. Balthrop is chairman of the board of directors of Agendia and Discovery Life Sciences. He is also a member of the board of directors of Personalis and an executive advisor for Water Street Healthcare Partners. He served as president and CEO of Luminex from 2004 to 2014.

Richard Sandberg, the current chairman of Oxford Immunotec's board of directors, will remain a member of the board.

Jun 21, 2019

Puneet Sarin

BD has appointed Puneet Sarin the worldwide president of BD Biosciences. He will be responsible for driving the global strategic, operational, and commercial performance across BD Biosciences. Sarin was previously senior vice president and general manger of the chemistry and immunoassay business unit at Beckman Coulter. Prior to Beckman Coulter, he was at GE. 
Jun 21, 2019

Steven Daniel

Cofactor Genomics has appointed Steven Daniel as VP of business development. Daniel previously served as senior director of applied sciences and business development at ArcherDx. Prior to ArcherDx, he was VP of sales at Genos/Nantomics, senior director of pharma business development at Adaptive Biotechnologies, and held commercial roles at Life Technologies, AltheaDX, Metabolon, and Affymetrix.

Jun 19, 2019

Donald Berry

OTraces has announced that Donald Berry has joined its scientific advisory board. Berry is professor of biostatistics and founding chair of quantitative sciences at the University of Texas MD Anderson Cancer Center, bringing extensive cancer research and policy experience including work with the National Cancer Institute PDQ Screening and Prevention Committee. He has also worked closely with the FDA Center for Devices and Radiological Health, helping to set rigorous scientific and quality standards.

Jun 18, 2019

Maureen Cronin

Maureen Cronin has resigned from the board of Celcuity, the company said in a document filed with the US Securities and Exchange Commission. Cronin, who served as a directory since 2017, resigned on June 12. Her decision, Celcuity said, was not due to any disagreement with the company. 

 

Jun 17, 2019

Stefan Timmerman

Stefan Timmerman has been appointed CFO of Dutch transplantation and companion diagnostics firm Genome Diagnostics. Currently group controller of private equity firm Broadview Holding, Timmerman was previously controller at SNS bank. Before that, he held the same postition at ASN bank. 

Jun 14, 2019

Leena Das-Young

Guardant health said that Leena Das-Young is leaving her position as chief LUNAR officer and general manager at the company for personal reasons. She will continue her service with the firm through June 18, 2019. In connection with her departure, and in exchange for a customary release of claims, Das-Young will be entitled to certain benefits under the company’s executive severance plan, as well as the retention of certain relocation benefits previously provided to her.

Jun 11, 2019

Thomas Schinecker, Barbara Schädler, Michael Heuer, Stephan Feldhaus, Peter Voser

Thomas Schinecker has been appointed as CEO of Roche Diagnostics and a member of the firm's corporate executive committee, effective August 1. He will succeed Michael Heuer, who is retiring at the end of July. Schinecker is currently head of Centralized and Point of Care Solutions at Roche Diagnostics. Previously, he was general manager for Roche Diagnostics Germany, and before that, he held various management positions in marketing and sales as well as product development at Roche Diagnostics. He holds a PhD in molecular biology from New York University.

Barbara Schädler will become head of group communications and a member of Roche's enlarged Corporate Executive Committee, effective October 1. She will succeed Stephan Feldhaus, who will leave Roche at the end of September. Schädler is currently head of communications and public affairs at E.ON. Previously, she held communications manager positions at Lufthansa, SAP, and the German Federal Ministry of Finance. She holds a master's degree in economics from the University of Mainz.

Peter Voser will step down from the board of directors of Roche at the end of June due to his additional role as interim CEO of ABB.

Jun 11, 2019

Gail Marcus

Binx Health has appointed Gail Marcus to its board of directors. Marcus has held executive positions in a number of healthcare sectors, including services, diagnostics, healthcare provision, and managed care. She held leadership positions at United Healthcare, Cigna, and private equity-backed diagnostic organizations; has an academic appointment at Massachusetts College of Pharmacy and Health Sciences; and serves on the boards of Natera, Cambridge Epigenetix, and Triple S Management, a Blue Cross Blue Shield affiliate in Puerto Rico.

Jun 10, 2019

George Goedesky

George Goedesky has joined Affinity Biosensors as vice president of sales of marketing. He will lead the rollout of the LifeScale AST system for rapid antibiotic susceptibility tests. Most recently, Goedesky led the adoption of the Burker MALDII Biotyper platform in the Americas. The LifeScale AST platform is currently in US clinical trials for identifying targeted therapy for sepsis, Affinity Biosensors said. 

Jun 06, 2019

Eric d'Esparbes

Progenity has hired Eric d'Esparbes as its senior VP and CFO. Prior to Progenity, d'Esparbes served as CFO and interim principal executive officer at Innoviva. Before Innoviva, he held roles as CFO at Joule Unlimited, VP of finance at AEI, and CFO for Meiya Power Company. 

Jun 05, 2019

David King, Adam Schechter

David King is retiring from Laboratory Corporation of America as its president and CEO on Oct. 31 and will become its executive chairman of the board, effective Nov. 1, the company said this week. Adam Schechter will succeed King as president and CEO on that day.

King became CEO of LabCorp on Jan. 1, 2007. Prior to that he was the firm's executive vice president and COO, as well as its executive VP of strategic planning and corporate development. He joined the company as senior VP, general counsel, and chief compliance officer in 2001, and was LabCorp's principal outside legal counsel for several years before that.

The company noted that it has tripled in sized under King's leadership. It does business in more than 100 countries now, employs almost 61,000 employees, and recorded revenue of more than $11 billion in 2018.

Schechter is currently the lead independent director of LabCorp's board, which expects to choose another board member to be the lead independent director at a later date. Schechter, who has been a LabCorp director for six years, was formerly Merck executive vice president and president of global human health.

Jun 04, 2019

Michael Lee Astion, Sterling Bennett, and Others

The Project Santa Fe Foundation has expanded its board of directors. The new board members are Michael Lee Astion, a professor and medical director in the department of laboratories at Seattle Children's Hospital; Sterling Bennett, adjunct associate professor in the department of pathology at the University of Utah School of Medicine, and medical director at Intermountain Healthcare central laboratory; and Mark Fung, a professor and vice chair for population health in the department of pathology and laboratory medicine at the Robert Larner M.D. College of Medicine at the University of Vermont.

Also named to the board were Curtis Hanson, a professor and vice chair, extramural laboratory affairs, department of laboratory medicine and pathology at Mayo Clinic, and chief medical officer at Mayo Clinic Laboratories; and Karen Kaul, the Duckworth Family Chair of Molecular Pathology, chair of pathology and laboratory medicine at NorthShore University HealthSystem, and clinical professor of pathology at the University of Chicago Pritzker School of Medicine.

May 30, 2019

Frank Ong

Frank Ong has joined EverlyWell, a home-based testing firm, as its chief medical and chief scientific officer. Ong previously held leadership positions at Guardant Health, Roche Diagnostics, and Illumina. Last month, the Austin, Texas-based firm said that it raised $50 million in private financing. 

May 30, 2019

Padma Sundar, Kim Dickinson

OncoCyte has appointed Padma Sundar as its senior VP of marketing and market access. The firm has also appointed Kim Dickinson as its VP of clinical operations.

Prior to OncoCyte, Sundar served as VP of strategy and market access at CellMax Life. Before CellMax, she acted as director of marketing at Guardant Health. Prior to Guardant, Sundar served as senior director at Roche Sequencing. She also held the role of senior director for Affymetrix's oncology portfolio.

Before OncoCyte, Dickinson served as VP of research and development and chief pathologist at Biocare Medical. Prior to BioCare, she served as VP of clinical operations at Roche Tissue Diagnostics. She also served as medical director for Laboratory Corporation of America' clinical trials division. Before working at LabCorp, Dickinson acted as medical director at Esoteric Testing. Prior to Esoteric, Dickinson worked at Quest Diagnostics, Citrus Valley Medical Center, and Pioneer Hospital.

May 29, 2019

Steven Kafka

ArcherDx has appointed Steven Kafka as executive chairman of its board of directors. Kafka will replace Kyle Lefkoff, founder and general partner of Boulder Ventures. Lefkoff will remain on the board of ArcherDx. Kafka currently serves as a partner at Third Rock Ventures. Prior to Third Rock Ventures, Kafka served as president and chief operating officer at Foundation Medicine. Prior to Foundation, Kafka held executive roles at several public and private oncology drug discovery and development companies.

Pages